Table 2. .
Results in recent studies in childhood and AYA NPC patients
| N | Type of study | Stage | Age (years) | Treatment | OS | DFS | |
| Jouin, 201942 | 95 | Retrospective | All M0 | Med. 15 y. | CT (90%) +RT/CT (59%) +IFN (18%) |
five y : 94% | five y : 91% |
| Qiu, 20171 | 176 | Retrospective | All M0 | 7–20 y. 24% < 14 y. |
CT +RT : 28% CT +RT/CT : 44% RT/CT : 23% |
five y : 76–90% | five y : 71–86% |
| Sahai, 20179 | 41 | Retrospective | 1/41 M1 (3%) | 6–20 y. Med. 14 y. 34% < 12 y. |
CT +RT/CT (68%)a | three y : 84% | three y : 56% |
| Guo, 201645 | 95 | Retrospective | All M0 | <25 y. 30% < 18 y. |
CT (100%) +RT/CT (52%) +adj. CT (30%) |
four y : 91% | 4y : 79% |
| Chen, 201528 | 32 | Retrospective | All M0 | 11 to 18 y. Mean 15 y. |
CT+ RT/CT (40%) or CT +RT + CT (31%)* |
five y : 86% III - 65% IV | NR |
| Liu, 201427 | 158 | Retrospective | All M0 | 8 to 20 y. Median 16 y. |
RT/CT 46% RT alone 54% |
five y : 83% | NR |
| Daoud, 201374 | 69 | Retrospective | All M0 | 10 to 20 y. | RT + CT 85% RT/CT 7% |
five y : 66% | five y : 66% |
| Hu, 2013 (78) | 95 | Retrospective | All M0 | 9 to 20 y. 16 y. |
CT + RT (38%)or RT alone (62%) |
five y : 54% | four y : 49% |
| Casanova, 20123 | 46 | Prospective | 5/46 M1 (10%) | 9 to 17 y. Med 13 y. |
CT +RT/CT | five y : 81% | five y 87% (M0) and 20% (M1) |
| Buerhlen, 201211 | 45 | Prospective | All M0 | 8 to 20 y. Med.15 y. |
CT + RT+IFN | 30 m : 97% | 30 m 92% |
| Cheuk, 201112 | 59 | Retrospective | 2/59 M1 (3%) | Med. 14 y. | CT +RT/CT (88%) RT alone (12%) |
15 y : 67% With cisplatin : 81% Without cisplatin : 54% |
15 y : 63% |
| Afqir, 200910 | 46 | Retrospective | 4/46 M1 (9%) | Med.16 y. | CT +RT | five y : 73% | five y : 41% |
| Orbach, 200813 | 34 | Retrospective | 1/34 M1 (3%) | Med.12 y. | RT +CT (91%) or RT 9% |
five y : 75% | five y : 73% |
| Rodriguez Galindo, 20054 | 17 | Prospective | All N2/N3 and/or M0/1 | Med. 13 y. | CT +RT | four y : 77% | four y : 75% |
| Mertens, 200514 | 59 | Prospective | All M0 | Med. 13 y. | CT +RT + IFN | nine y : 95% | nine y : 91% |
AYA, adolescents and young adults; CT, chemotherapy; DFS, disease-free survival; IFN, interferon; MO, no mets; N, number of patient; NPC, nasopharyngeal carcinoma; NR, not reported; OS, overall survival; RT, radiotherapy; adj CT, adjuvant chemotherapy.
a
other patients treated with various RT/CT sequences